Kornimate/medical-research-clean huggingface dataset:
effect of strawberries on cardiovascular disease risk

Conditions: Cardiovascular Disease

Summary: it is important to identify and evaluate foods, such as strawberries, that can improve established and emerging cardiovascular risk factors, such as postprandial lipid and glycemic responses, and vascular health. postprandial derangements may affect multiple metabolic pathways that lead to increased arterial stiffness. research has demonstrated the potential of strawberries to ameliorate postprandial responses to a high fat/high glucose meal. further research is needed to demonstrate this effect in better controlled clinical studies and explore whether metabolic effects lead to improved arterial health. the investigators propose to examine the effects of adding 40 g of freeze-dried strawberry powder to a high fat/high glucose meal on postprandial cardiovascular risk factor including lipids, insulin, glucose, and arterial stiffness and central blood pressure. the investigators hypothesize that the bioactive components of strawberry powder will attenuate postprandial lipemic and glycemic responses, as well as improve measures of arterial health.


Eligibility criteria:
inclusion criteria: * 20-50 years of age * ldl-c below 160 mg/dl * triglycerides below 350 mg/dl * no stage ii hypertension (bp below 160/100 mmhg) * not taking medication for elevated lipids, blood pressure, or glucose exclusion criteria: * allergies to strawberries * known intolerance to high fat meals * history of cardiovascular disease, kidney disease, diabetes or inflammatory diseases such as gi disorders and arthritis * use of non-steroidal anti-inflammatory or immunosuppressant drugs * conditions requiring the use of steroids * use of medication or supplements for elevated lipids, blood pressure or glucose
gene expression in tumor tissue from women undergoing surgery for breast cancer or core biopsy of the breast

Conditions: Breast Cancer

Summary: rationale: studying samples of breast tissue in the laboratory may help doctors learn more about the genes and proteins found in breast tissue. purpose: this phase i trial is studying genes and proteins in breast tissue from women undergoing surgery for breast cancer or core biopsy of the breast.

objectives: * assess tumor gene expression information from women undergoing surgery for breast cancer or core biopsy sampling of the breast. outline: this is a pilot study. tumor tissue is collected and analyzed for tumor gene expression by dna microarray analysis for research studies. projected accrual: a total of 100 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * undergoing surgery for breast cancer or core biopsy sampling of the breast patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: breast cancer
efficacy of low-level light therapy in reducing dry eye in patients undergoing cataract surgery

Conditions: Dry Eye

Summary: the goal of this clinical trial is to evaluate the effectiveness of low level light therapy (lllt) in reducing the incidence or alleviating the severity of ded due to meibomian gland dysfunction in otherwise healthy patients undergoing cataract surgery. participants will be randomly assigned in a 1:1 ratio to either a treatment group or a control group. the treatment group will receive lllt one week before and one week after cataract surgery; the control group will not recieve lllt at any time. researchers will compare the treatment and the control group to see if patients receiving lllt present with reduced signs and symptoms of ocular surface dysfunction with respect to the control group.


Eligibility criteria:
inclusion criteria: * healthy patients affected by senile cataract * patients scheduled for phacoemulsification and intraocular lens implantation exclusion criteria: * any other ocular comorbidity (e.g. glaucoma), * chronic instillation of eye drops of any type * previous ocular surgery or trauma to the addressed eye * previous cataract surgery in the controlateral eye, * active ocular infections * use of systemic drug with a known or suspected link to dry eye (e.g. diuretics, antidepressants, antihistamines, hormone replacement therapy) * autoimmune diseases (e.g. sjögren syndrome) * intraoperative complications (e.g. capsular bag rupture requiring vitrectomy, suprachoroidal hemorrhage) * postoperative complications (e.g. endophthalmitis, vitritis)
effect of saline irrigation in reducing choledocholithiasis recurrence after ercp

Conditions: Stone - Biliary

Summary: in this prospective study, the investigators assessed the utility of intermittent saline irrigation in reducing the recurrent rate of choledocholithiasis after the endoscopic extraction for common bile duct stones, and it does not increase the rate of procedure-related complications.

in recent years, an endoscopic retrograde cholangiopancreatography (ercp) is the golden standard procedure to remove the common bile duct stones(cbd). nevertheless, it is reported that the recurrence rate of cbd stones is 4% to 24% after ercp. the contributing factors were periampullar diverticulum, situ gallbladder, and incomplete cbd stone clearance. the main reason of stone recurrence is incomplete cbd stone clearance including remnant stone fragments themselves and tinny fragments can act as a nidus for further cbd stone growth. it is difficult to retrieve these fine fragments completely using conventional devices such as retrieval basket and ballon. therefore, the investigators attempt to remove residual stone fragments by means of saline infusion. saline irrigation has many advantages such as better effect and less side effect and no extra cost. it is reported that use intraductal ultrasonography (idus) to demonstrate residual cbd stones. however, idus has limited availability in clinical practice. the single-operator cholangioscopy (soc)-system gains widespread acceptance because of its independent washing channels and direct viewing. the purpose of this study is to evaluate whether saline solution irrigation would decrease the recurrent rate of choledocholithiasis after endoscopy retrieval stones.

Eligibility criteria:
inclusion criteria: * with ercp indications * with mechanical lithotripsy during operation exclusion criteria: * unwillingness or inability to consent for the study * unstable vital signs * coagulation dysfunction (inr\>1.5) and low peripheral blood platelet count (\<50×10 \^9 / l) or using anti-coagulation drugs * prior surgery of bismuth ⅱ, roux-en-y and cholangiojejunostomy * preoperative coexistent diseases: acute pancreatitis, gi tract hemorrhage, severe liver disease (such as decompensated liver cirrhosis, liver failure and so on), septic shock * biliary-duodenal fistula confirmed during ercp * pregnant women or breastfeeding

Keywords: ercp common bile duct stone cholangitis residual stone irrigation recurrence
single-arm clinical trial of tace in combination with acoradine as adjuvant therapy after surgery in patients with hepatocellular carcinoma at high risk of recurrence

Conditions: Hepatocellular Carcinoma (HCC)

Summary: to assess 1-year recurrence-free survival (rfs) in patients with hepatocellular carcinoma (hcc) who are at high risk of inguinal orchiectomy recurrence usingtace combined with acoradine


Eligibility criteria:
inclusion criteria: 1. the subjects voluntarily cooperated with the study and signed the informed consent, 2. male or female, 18 years old ≤ age ≤75 years old, 3. the histopathologic diagnosis was hepatocellular carcinoma 4. r0 resection was performed within 4 to 8 weeks before recruitment (patients who were confirmed to have r0 resection by imaging and pathological examination were excluded from the study group if the residual r1, residual r2 or the margin of resection were not clear) 5. to satisfy any of the following high risk factors for postoperative recurrence of hepatocellular carcinoma: i) bclc stage b (\&gt; 3 tumors, regardless of size or number, at least one of which is \&gt; 3 cm in diameter) ; ii) single tumor ≥5 cm in diameter; iii) intraoperative or postoperative pathological findings of vascular invasion (including microvascular invasion and vp1/vp2 portal vein invasion) ; iv) histopathologic grade of low differentiation; v) capsular invasion or loss with unclear border; vi) direct invasion of adjacent organs 6. ecog performance status score of 0-1 and child-pugh score of 5-6 7. none of the patients had received anti-tumor therapy for hepatocellular carcinoma, including systemic therapy and local therapy (except for 1-2 prophylactic tace or haic 4-8 weeks after radical therapy) . 8. subjects who received radical therapy, if required, were allowed to receive 1-2 prophylactic tace/haic treatments 4-8 weeks after surgery (on demand and not necessarily) exclusion criteria: 1. known sarcomatoid hepatocellular carcinoma/mixed hepatocellular carcinoma-cholangiocarcinoma/fibrolamellar hepatocellular carcinoma; 2. a history of other malignancies in the past 5 years or at the same time; 3. severe functional impairment of other important organs such as heart, brain, lung and kidney; 4. patients with a history of immunodeficiency or autoimmune disease; 5. evidence of tumor recurrence or metastasis before enrollment; 6. known hypersensitivity to active ingredients, excipients, or history of severe allergy to any other monoclonal antibody, anti-angiogenic drugs; 7. patients with a history of hepatic encephalopathy;

Keywords: hepatocellular carcinoma,rfs,adjuvant therapy after surgery
cardiovascular effects of cart cell therapy

Conditions: Leukemia; Lymphoma; Cardiotoxicity; Risk Factor, Cardiovascular; Immunotherapy

Summary: this is an observational study aiming to prospectively define the rate of occurrence, natural history and progression of cardiac dysfunction in adults, and to identify the patients at high risk of developing cardiovascular events. the study enrolls patients prior to infusion with cart cell therapy and follows them with serial echocardiography, cardiac biomarkers, clinical data, and quality of life questionnaire.

patients have echo, blood draw, and qol survey prior to cart infusion, then 2 days, 1 week, 1 month and 6 months following cart infusion. if patients experiences crs, study team acquires echo within 72 hours of onset. as part of an optional substudy, patients wear an event monitor for 10 days, starting day of cart infusion.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * diagnosed with cd19+ malignancy undergoing treatment with cart cells exclusion criteria: * unable to provide informed consent

Keywords: cardiotoxicity of cancer therapy cardio-oncology cart cell therapy
measurement of antioxidant activity on postoperative inflammation in patients undergoing ophthalmic surgery

Conditions: Cataract; Myopia

Summary: this trial hypothesized that novel laser refractive surgery techniques (prk, lasik, smile) or laser-assisted cataract surgery (flacas) could suppress postoperative inflammation and improve recovery in patients by reducing oxidative stress generated by the surgical procedure. it is also intended to verify whether the new laser technology is necessary for clinical use in groups with low antioxidant activity through the detection of antioxidant activity in the eyes of patients.


Eligibility criteria:
inclusion criteria: * over 20 years old (included) * corneal refractive surgery or cataract surgery patients exclusion criteria: * patients with eye infections * presence of severe retinal disease * presence of severe eye injury or severe ptosis

Keywords: antioxidants
comparison of two treatment regimens in patients with type 2 diabetes after short-term intensive insulin therapy

Conditions: Type 2 Diabetes Mellitus

Summary: primary objective: to test the hypothesis that basal insulin based treatment (g+) is noninferior to twice-daily premixed insulin (pm-2) in term of hemoglobin a1c (glycosylated hemoglobin, hba1c) reduction from baseline to end of study. the test for superiority can be done if noninferiority is achieved. secondary objectives: * to assess efficacy in terms of percentage of patients achieving hba1c \<7% and hba1c \<7% without hypoglycemia. * to assess efficacy in terms of percentage of patients achieving fasting plasma glucose (fpg) \<7 mmol/l and fpg \<7 mmol/l without hypoglycemia. * to assess safety in term of occurrence of moderate/severe hypoglycemia. * to assess daily blood glucose (bg) variation. * to assess patient satisfaction.

the duration of study is approximately 21 months. each patient will be followed for approximately 27 weeks from screening visit to end-of-study

Eligibility criteria:
inclusion criteria : * patients with age between 18 and 70 years. * hemoglobin a1c\>7.5%, and ≤11%. * fasting plasma glucose \>7 mmol/l. * fasting c peptide \>1 ng/ml. * type 2 diabetes (t2dm) patients with diabetes diagnosis between 2 and 10 years (world health organization 1999 t2dm diagnose criteria). * continuous treatment with stable doses of metformin (≥1 g/day) and 1 oral antihyperglycemic drug (at least half maximum dose) for more than 3 months prior to screening. * body mass index ≥21 kg/m2, and \<40 kg/m2. exclusion criteria: * more than 7 consecutive days of insulin treatment within the 12 months except for acute disease or surgery. * diabetes other than t2dm (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake). * history of hypoglycemia unawareness or recurrent hypoglycemia or severe hypoglycemia within the past 12 months. * history of sensitivity to the study drugs or to drugs with a similar chemical structure. * pregnancy or planned pregnancy or current lactation (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method). * acute diabetic complications (diabetic ketoacidosis, lactic acidosis, hyperosmolar nonketotic diabetic coma) within the past 12 months. * significant diabetic complications and serious disease, e.g., symptomatic autonomic neuropathy, gastroparesis, unstable angina or active proliferative retinopathy. * acute infections which may affect bg control within the past 4 weeks. * active liver disease, alanine transaminase (alt) and/or aspartate aminotransferase (ast) greater than two times the upper limit of the reference range at screening. * impaired renal function, defined as but not limited to, serum creatinine levels ≥1.5 mg/dl (132 μmol/l) for males and ≥1.4 mg/dl (123 μmol/l) for females or presence of macroproteinuria (\>2 g/day). the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
effect of ozone gel on treatment of chronic periodontitis

Conditions: Periodontal Diseases

Summary: to evaluate the efficacy of locally delivered ozone gel as an adjunct to conventional periodontal therapy on selected clinical parameters as well as alveolar bone density (bd) and superoxide dismutase (sod) activity in patient with chronic periodontitis.

in this study, the investigators tested the effect of ozone gel as a local delivery system in treatment of chronic periodontitis in term of probing pocket depth reduction, mean gain in clinical attachment level, a more rise in bd values as well as greater reduction in sod activity compared to scaling and root planing (srp) alone.

Eligibility criteria:
inclusion criteria: 1. the participant's age ranged between 30 and 60 years. 2. all of the patients suffered from chronic periodontitis with attachment loss ≥ 5mm. 3. willingness to participate and sign the informed consent. exclusion criteria: 1. any systemic disease that affect the periodontium. 2. pregnancy, lactation, postmenopausal women 3. people who take anti-inflammatory drugs, antibiotics or vitamins within the previous 3 month. 4. people who use mouth washes regularly 5. heavy smoking (\> 10 cigarettes/day) 6. history of alcohol abuse. 7. participation in other clinical trials.

Keywords: ozone gel antioxidants chronic periodontitis superoxide dismutase
genetic markers of diabetic ulcers and personalized treatment targets research

Conditions: Diabetic Ulcers

Summary: this clinical trial involves collecting peripheral blood, ulcer tissue, and fecal samples from diabetic ulcer patients for bioinformatics analysis to screen genetic markers significantly associated with ulcer risk and healing differences. furthermore, multi-omics data will be integrated to establish a diabetic ulcer risk prediction model. based on key single nucleotide polymorphisms and their regulatory pathways, potential new drug targets for promoting healing will be explored, providing a genetic basis for personalized treatment.


Eligibility criteria:
inclusion criteria: * 1) subjects who voluntarily participate in this clinical study and sign informed consent; * 2) patients with type 2 diabetes and diabetic ulcers; * 3) disease duration ≥ 10 years or age ≥ 55 years at enrollment; * 4) inpatient or outpatient who can be monitored by the same investigating team throughout the duration of the study. exclusion criteria: * 1) severe vascular occlusion or impairment; * 2) patients with congenital heart disease, aortic dissection, or other severe cardiovascular diseases; * 3) patients with ulcers caused by factors other than diabetes; * 4) patients with severe liver and kidney dysfunction or serious neurological impairment.

Keywords: diabetic ulcers
efficacy of 25% trichloroacetic acid peel versus 30% salicylic acid peel in mild to moderate acne vulgaris

Conditions: Acne Vulgaris

Summary: to compare the efficacy of 25% trichloroacetic acid peel versus 30% salicylic acid peel in mild to moderate acne vulgaris. study design: randomized control trial. place and duration of study: department of dermatology, cmh abbottabad from 01 jun 2022 to 30th nov, 2022. methodology: a total of 60 patients presented with mild or moderate acne vulgaris were randomized into two groups comprising 30 patients in each group and treated with either the tca peel or the sa peel at 2-week intervals for 12 weeks. patients in group a were treated with 25% tca peel whereas patients in group b were treated with 30% sa peel. at the end of therapy after 12 weeks, evaluation of active acne was done by individual lesion counts (comedones, papules and pustules) and calculation of the michaelsson acne score (mas).


Eligibility criteria:
inclusion criteria: * patients with mild or moderate facial acne vulgaris presented in dermatology opd exclusion criteria: * patients with grade iii or iv acne vulgaris * patients taking any acne medications or had taken oral or topical medications in the past 4 weeks * pregnant female patients or nursing a baby * patients with known hypersensitivity to the formulations used in the study or a history of photosensitivity * hypertrophic scars, keloidal tendency, active or recurrent herpes simplex infection * active dermatosis * unrealistic expectations
long-term safety and effectiveness of augment® injectable bone graft compared to autologous bone graft

Conditions: Ankle and Hindfoot Arthrodesis

Summary: the objective of this long-term study is to evaluate the long-term effectiveness and safety of augment® injectable bone graft vs. autologous bone graft. the study involves evaluation of subjects originally treated under protocol bmti-2009-01 or bmti-2010-01 or treated with autograft under protocol bmti-2006-01. subjects will be asked to consent and return to provide long-term follow-up data at or after 60 months (5 years) have elapsed since their original surgery as a subject in protocol bmti-2009-01 or bmti-2010-01. study hypothesis: the effectiveness and safety profile for augment® injectable bone graft is maintained and remains comparable to that of autologous bone graft over long-term subject follow-up. regulatory phase: post-approval study


Eligibility criteria:
inclusion criteria: 1. must be willing and able to provide informed consent and be available for the planned follow-up evaluations and radiologic tests; and 2. must have been included in the augment injectable propensity score matching population from the augment injectable summary of safety and effectiveness data (ssed). exclusion criteria: 1) subjects that were excluded from the safety analysis in the bmti-2009-01 or bmti-2010-01 study. these subjects were consented, but never treated as part of the bmti-2009-01 or bmti-2010-01 protocol.

Keywords: ankle fusions augment® injectable bone graft autologous bone graft arthritis ankle pain foot pain hindfoot fracture ankle fracture
single dose study with 4sc-203 in healthy volunteers

Conditions: Acute Myeloid Leukemia

Summary: the purpose of the study is to evaluate safety and tolerability of 4sc-203 after a single dose administration in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy male subjects aged 18 to 45 years (included), and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening * subjects must be able to communicate well with the investigator, to understand and comply with the requirements of the study, and to understand and sign the written informed consent exclusion criteria: * evidence of current or previous clinically significant disease, medical condition or finding of the medical examination (including vital signs and ecg), that in the opinion of the investigator would compromise the safety of the subject or the quality of the data * current or recent history of significant renal, hepatic, haematological, immunological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the subject's participation in the trial

Keywords: 4sc-203 phase i single dose healthy volunteers